Johnson & Johnson has pulled ahead of rival AstraZeneca Plc in a race to dominate the blockbuster market for lung cancer ...

This week Bobbi Conner talks with Dr. Miriam Alexander about advances in lung cancer treatment in recent years. Dr. Alexander ...

First-line Rybrevant plus Lazcluze significantly extended overall survival versus Tagrisso in mutated, advanced or metastatic non-small cell lung cancer.

Researchers conducted a prospective, longitudinal cohort study involving individuals with current or former habit, who had ...

Subcutaneous pembrolizumab reduces time demands for both the patient and clinician, all while providing a consistent efficacy ...

Johnson & Johnson's MARIPOSA study shows Rybrevant plus Lazcluze significantly extends overall survival in first-line ...

AstraZeneca presented new data on TAGRISSO® (osimertinib) at the European Lung Cancer Congress (ELCC) 2025, reinforcing its ...

The COCOON trial regimen reduced dermatologic side effects in patients with EGFR-mutant non-small cell lung cancer, phase 2 ...

BioNTech has shown why it made small cell lung cancer (SCLC) a priority for its PD-L1xVEGF-A bispecific. | BioNTech has shown ...

Drug Improves Effectiveness of Radiation for Lung Cancer That Has Spread to the Brain Oct. 4, 2024 — The University of Cincinnati's Debanjan Bhattacharya is first author of new research ...

The New York State Senate has unanimously passed Senate Bill S. 2000, a significant step toward improving the early detection ...

The battle against drug resistance in lung cancer therapy remains a critical issue in oncology, with resistance mechanisms ...